Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

2009 ◽  
Vol 86 (2) ◽  
pp. 175-182 ◽  
Author(s):  
S A Stoch ◽  
S Zajic ◽  
J Stone ◽  
D L Miller ◽  
K Van Dyck ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Phase I ◽  
Postmenopausal Women ◽  
Cathepsin K ◽  
Double Blind ◽  
Phase I Studies ◽  
Cathepsin K Inhibitor

A randomized, double-blind, placebo-controlled study of a cathepsin-K inhibitor in the treatment of postmenopausal women with Low BMD: 18 month results

Bone ◽  
2008 ◽  
Vol 42 ◽  
pp. S74
Author(s):  
Avery Ince ◽  
Michael McClung ◽  
Henry Bone ◽  
Nadia Verbruggen ◽  
Andrea Rybak-Feiglin ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Cathepsin K ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Cathepsin K Inhibitor

scholarly journals Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption

1996 ◽  
Vol 42 (10) ◽  
pp. 1639-1644 ◽  
Author(s):  
M Bonde ◽  
C Fledelius ◽  
P Qvist ◽  
C Christiansen
Keyword(s):  
Bone Resorption ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Premenopausal Women ◽  
Type I ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Analytical Recovery ◽  
Controlled Clinical Study ◽  
Different Doses

Abstract We present a coated-tube RIA that is useful for assessment of bone resorption. The assay uses a monoclonal antibody raised against a linear 8-amino-acid sequence (EKAHDGGR) derived from the C-telopeptides of type I collagen. Within-run and total CVs were 4.4% and 5.3-6.2%, respectively, at concentrations of 1-7 mg/L (n = 4-20). Analytical recovery was 98% +/- 8% and dilution 97% +/- 7%. Values obtained in a group of 36 premenopausal women were 227 +/- 89.6 mg/mol creatinine. In a group of 141 postmenopausal women, the values obtained were 429 +/- 225 mg/mol creatinine, a highly significant increase of 89% (P <0.001) over the premenopausal value. In a double-blind placebo-controlled clinical study of these postmenopausal women receiving five different doses of a bisphosphonate, a significant decrease of RIA-measured C-telopeptide values was seen in all bisphosphonate-treated groups, after just 3 months. Values in urine samples from postmenopausal women assayed with the RIA (gamma) and the CrossLaps(TM) ELISA (x) agreed well: slope = 0.98 (95% confidence interval, 0.94-1.01), intercept = 0.34 (0.25-0.43) mg/L, and Sylx = 0.93 mg/L (n = 678). We conclude that this RIA represents a valuable tool for assessing bone resorption.

Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5year results of a phase 2 trial

Bone ◽  
2012 ◽  
Vol 51 (6) ◽  
pp. S12
Author(s):  
H. Resch ◽  
N. Binkley ◽  
H. Bone ◽  
J.A. Eisman ◽  
N. Gilchrist ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Cathepsin K ◽  
Phase 2 ◽  
Cathepsin K Inhibitor ◽  
Phase 2 Trial

scholarly journals POTASSIUM CITRATE DECREASES BONE RESORPTION IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL

2015 ◽  
Vol 21 (12) ◽  
pp. 1380-1386 ◽  
Author(s):  
Naina Sinha Gregory ◽  
Rekha Kumar ◽  
Emily M. Stein ◽  
Ellen Alexander ◽  
Paul Christos ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bone Resorption ◽  
Postmenopausal Women ◽  
Potassium Citrate ◽  
Double Blind ◽  
Double Blind Clinical Trial
Sign in / Sign up

Export Citation Format

Share Document